uveal neoplasms

Summary

Summary: Tumors or cancer of the UVEA.

Top Publications

  1. pmc Mutations in GNA11 in uveal melanoma
    Catherine D Van Raamsdonk
    Department of Medical Genetics, University of British Columbia, Vancouver, Canada
    N Engl J Med 363:2191-9. 2010
  2. pmc Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
    Catherine D Van Raamsdonk
    Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T1Z3, Canada
    Nature 457:599-602. 2009
  3. pmc Frequent mutation of BAP1 in metastasizing uveal melanomas
    J William Harbour
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 330:1410-3. 2010
  4. ncbi The genetics of uveal melanoma: an emerging framework for targeted therapy
    J William Harbour
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO, USA
    Pigment Cell Melanoma Res 25:171-81. 2012
  5. pmc Germline BAP1 mutations predispose to malignant mesothelioma
    Joseph R Testa
    Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Nat Genet 43:1022-5. 2011
  6. ncbi Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases
    Julien Trolet
    Department of Bioinformatics, Institut Curie, Paris, France
    Invest Ophthalmol Vis Sci 50:2572-80. 2009
  7. pmc Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
    J William Harbour
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri, USA
    Nat Genet 45:133-5. 2013
  8. ncbi Uveal melanoma: trends in incidence, treatment, and survival
    Arun D Singh
    Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Ophthalmology 118:1881-5. 2011
  9. ncbi Very long-term prognosis of patients with malignant uveal melanoma
    Emma Kujala
    Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland
    Invest Ophthalmol Vis Sci 44:4651-9. 2003
  10. ncbi MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met
    Dongsheng Yan
    School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical College, Wenzhou, Zhejiang, People s Republic of China
    Invest Ophthalmol Vis Sci 50:1559-65. 2009

Research Grants

  1. OCULAR MELANOMA
    Paul Finger; Fiscal Year: 2003
  2. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2010
  3. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
  4. THE ROLE OF RB IN THE RETINA & OTHER TISSUES
    JAMES HARBOUR; Fiscal Year: 2009
  5. MICROCIRCULATION OF UVEAL MELANOMA
    Robert Folberg; Fiscal Year: 2007
  6. Control of Eye Melanoma Metastsis
    Hans E Grossniklaus; Fiscal Year: 2010
  7. Control of Eye Melanoma Metastasis
    Hans Grossniklaus; Fiscal Year: 2003
  8. SUBMACULAR SURGERY TRIALS PATHOLOGY CENTER
    Hans Grossniklaus; Fiscal Year: 2003
  9. Thyroid Stimulating Hormone Promotes the Growth and Progression of Human Melanoma
    Julie Ellerhorst; Fiscal Year: 2008
  10. Autoimmune Mechanisms in the Response to Renal Cancer
    Julie Ellerhorst; Fiscal Year: 2006

Detail Information

Publications264 found, 100 shown here

  1. pmc Mutations in GNA11 in uveal melanoma
    Catherine D Van Raamsdonk
    Department of Medical Genetics, University of British Columbia, Vancouver, Canada
    N Engl J Med 363:2191-9. 2010
    ..Uveal melanoma is the most common intraocular cancer. There are no effective therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas...
  2. pmc Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
    Catherine D Van Raamsdonk
    Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T1Z3, Canada
    Nature 457:599-602. 2009
    ..Our results demonstrate an alternative route to MAP kinase activation in melanocytic neoplasia, providing new opportunities for therapeutic intervention...
  3. pmc Frequent mutation of BAP1 in metastasizing uveal melanomas
    J William Harbour
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 330:1410-3. 2010
    ..These findings implicate loss of BAP1 in uveal melanoma metastasis and suggest that the BAP1 pathway may be a valuable therapeutic target...
  4. ncbi The genetics of uveal melanoma: an emerging framework for targeted therapy
    J William Harbour
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO, USA
    Pigment Cell Melanoma Res 25:171-81. 2012
    ..These mutations appear to be key events that provide the potential for targeted therapy. This article will review the genetic findings in uveal melanoma over the past two decades and suggest important areas for future work...
  5. pmc Germline BAP1 mutations predispose to malignant mesothelioma
    Joseph R Testa
    Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Nat Genet 43:1022-5. 2011
    ..We hypothesize that other cancers may also be involved and that mesothelioma predominates upon asbestos exposure. These findings will help to identify individuals at high risk of mesothelioma who could be targeted for early intervention...
  6. ncbi Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases
    Julien Trolet
    Department of Bioinformatics, Institut Curie, Paris, France
    Invest Ophthalmol Vis Sci 50:2572-80. 2009
    ..The purpose of this study was to analyze genomic profiles in a large series of ocular tumors and liver metastases and design a genome-based classifier for metastatic risk assessment...
  7. pmc Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
    J William Harbour
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri, USA
    Nat Genet 45:133-5. 2013
    ..Thus, uveal melanoma is among a small group of cancers associated with SF3B1 mutations, and these mutations denote a distinct molecular subset of uveal melanomas...
  8. ncbi Uveal melanoma: trends in incidence, treatment, and survival
    Arun D Singh
    Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Ophthalmology 118:1881-5. 2011
    ..To determine trends in incidence, treatment, and survival with primary uveal melanoma in the United States over a 36-year period from 1973 to 2008...
  9. ncbi Very long-term prognosis of patients with malignant uveal melanoma
    Emma Kujala
    Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland
    Invest Ophthalmol Vis Sci 44:4651-9. 2003
    ..To investigate the very long-term prognosis of patients with uveal melanoma and the clinical characteristics influencing it...
  10. ncbi MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met
    Dongsheng Yan
    School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical College, Wenzhou, Zhejiang, People s Republic of China
    Invest Ophthalmol Vis Sci 50:1559-65. 2009
    ..MicroRNA-34a (miR-34a), a potential key effector of the p53 tumor-suppressor gene, was studied as a potential tumor suppressor in uveal melanoma...
  11. ncbi Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma
    Xiaoyan Chen
    School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical College, Wenzhou, Zhejiang, China
    Invest Ophthalmol Vis Sci 52:1193-9. 2011
    ..The authors' previous studies on miR-34a showed that miRNA can influence the growth of uveal melanoma cells. In this study, they investigated the role of miR-137 in the pathogenesis of uveal melanoma...
  12. pmc Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
    Mohamed H Abdel-Rahman
    Department of Ophthalmology, The Ohio State University, Columbus, Ohio, USA
    J Med Genet 48:856-9. 2011
    ..To investigate the potential contribution of germline sequence alterations in the BAP1 gene in uveal melanoma (UM) patients with possible predisposition to hereditary cancer...
  13. ncbi Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells
    Mao Ye
    School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical College, Wenzhou, Zhejiang, PR China
    Invest Ophthalmol Vis Sci 49:497-504. 2008
    ..This study investigated the effect of hepatocyte growth factor (HGF)-triggered signaling pathways to identify the role of HGF and its downstream effectors in inducing the migration of uveal melanoma cells...
  14. ncbi Detection of M2-macrophages in uveal melanoma and relation with survival
    Inge H G Bronkhorst
    Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
    Invest Ophthalmol Vis Sci 52:643-50. 2011
    ..This study was conducted to determine whether the tumor-infiltrating macrophages in uveal melanoma are of this M2 subtype...
  15. pmc Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma
    Hua Yang
    Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA
    Invest Ophthalmol Vis Sci 51:2835-42. 2010
    ..This study was undertaken to determine whether anti-vascular endothelial growth factor (VEGF) therapy inhibits growth of primary uveal melanoma and spread of its hepatic micrometastases...
  16. pmc Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity
    Aizhi Zhu
    Department of Radiology, Emory University, Atlanta, Georgia 30322, USA
    J Med Chem 53:8556-68. 2010
    ..These data demonstrate that dipyrimidine amines are unique CXCR4 antagonists with high potency and specificity...
  17. ncbi Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma
    Jordan Madic
    Institut Curie, Paris, France
    Clin Cancer Res 18:3934-41. 2012
    ..To develop a molecular tool to detect circulating tumor-derived DNA (ctDNA) in the plasma from patients with uveal melanoma as a marker of tumor burden and monitor treatment efficacy...
  18. ncbi Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma
    Inge H G Bronkhorst
    Department of Ophthalmology, Leiden University Medical Center, The Netherlands
    Arch Pathol Lab Med 135:1042-7. 2011
    ..Fluorescence in situ hybridization (FISH) analyses on tumor sections and on isolated nuclei showed that even low numbers of cells with monosomy of chromosome 3 adversely affected survival...
  19. pmc Vasculogenic mimicry and tumor angiogenesis
    R Folberg
    Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA
    Am J Pathol 156:361-81. 2000
    ..The unique patterning characteristic of vasculogenic mimicry provides an opportunity to design noninvasive imaging techniques to detect highly aggressive neoplasms and their metastases...
  20. ncbi Effectiveness of treatments for metastatic uveal melanoma
    James J Augsburger
    Department of Ophthalmology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    Am J Ophthalmol 148:119-27. 2009
    ..To evaluate and comment on published peer-reviewed literature for evidence of effectiveness of treatments for metastatic uveal melanoma...
  21. ncbi Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival
    Paul R Van Ginkel
    Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA
    Cancer Res 64:128-34. 2004
    ..These data show that the Axl pathway mediates increased survival of uveal melanoma cells, potentially advantageous during cancer dormancy, and that Axl may function in part through regulation of Cyr61...
  22. pmc Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance
    Grazia Ambrosini
    Laboratory of New Drug Development and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin Cancer Res 18:3552-61. 2012
    ....
  23. pmc Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
    Erika von Euw
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, Los Angeles, CA, USA
    Mol Cancer 11:22. 2012
    ..TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2...
  24. ncbi Targeted therapy for uveal melanoma
    Pierre L Triozzi
    Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, United States
    Cancer Treat Rev 34:247-58. 2008
    ..Clinical trials of some of these approaches have been initiated in patients with metastatic uveal melanoma as well as in the adjuvant setting after primary therapy...
  25. ncbi The miRNA expression profile of the uveal melanoma
    Chenghsun Yang
    Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing 100730, China
    Sci China Life Sci 54:351-8. 2011
    ..The differentially expressed miRNAs may be involved in uveal melanoma pathogenesis, and may help promote the diagnosis and treatment for uveal melanoma...
  26. ncbi Functional significance of B7-H1 expressed by human uveal melanoma cells
    Renbing Jia
    Department of Ophthalmology, Ninth People s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, PR China
    Mol Med Rep 4:163-7. 2011
    ..This provides new insight into anti-tumor immunity against B7-H1-expressing UM cells...
  27. ncbi Survival rates with uveal melanoma in the United States: 1973-1997
    Arun D Singh
    Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Ophthalmology 110:962-5. 2003
    ..To determine variations in 5-year relative survival rates with primary uveal melanoma in the United States over a 25-year period from 1973 to 1997...
  28. ncbi Cytogenetics of uveal melanoma: a 7-year clinical experience
    Bertil Damato
    Ocular Oncology Service, Royal Liverpool University Hospital, Liverpool, United Kingdom
    Ophthalmology 114:1925-31. 2007
    ..Since 1999, we have offered cytogenetic analysis to patients treated by local resection or enucleation. This study correlated our cytogenetic results with clinical and histologic predictors and disease-specific mortality...
  29. pmc Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window
    S R Boyd
    Department of Pathology, Institute of Ophthalmology, University College London, Bath Street, London EC1V 9EL, UK
    Br J Ophthalmol 86:448-52. 2002
    ..Novel anti-VEGF therapies are now in clinical trial, and the authors therefore wished to determine whether VEGF-A was indeed elevated in melanoma bearing eyes...
  30. pmc Does ocular treatment of uveal melanoma influence survival?
    B Damato
    Ocular Oncology Service, Royal Liverpool University Hospital, Prescot St, Liverpool L7 8XP, UK
    Br J Cancer 103:285-90. 2010
    ..Randomised trials of treatment vs non-treatment of asymptomatic tumours are desirable but would be controversial, difficult, expensive and possibly inconclusive. Strategies for coping with uncertainty are needed to avoid unethical care...
  31. ncbi Molecular classification of cutaneous malignant melanoma by gene expression profiling
    M Bittner
    Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892, USA
    Nature 406:536-40. 2000
    ..Global transcript analysis can identify unrecognized subtypes of cutaneous melanoma and predict experimentally verifiable phenotypic characteristics that may be of importance to disease progression...
  32. ncbi Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification
    Justyna Dopierala
    Department of Pathology, School of Cancer Studies, University of Liverpool, Liverpool, UK
    Invest Ophthalmol Vis Sci 51:4898-905. 2010
    ..To determine intratumor genetic heterogeneity in uveal melanoma (UM) by multiplex ligation-dependent probe amplification (MLPA) in formalin-fixed, paraffin-embedded (FFPE) tumor tissues...
  33. ncbi Uveal and conjunctival malignant melanoma in Denmark, 1943-97: incidence and validation study
    P Isager
    Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
    Ophthalmic Epidemiol 12:223-32. 2005
    ..To study the incidence of malignant melanoma in the ocular region in Denmark during the period 1943-97...
  34. pmc Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression
    Rosaria Gangemi
    Immunological Therapy Laboratory, National Cancer Research Institute, University Hospital San Martino, Genoa, Italy
    PLoS ONE 7:e29989. 2012
    ..These results suggest that mda-9/syntenin is involved in uveal melanoma progression and that it warrants further investigation as a candidate molecular marker of metastases and a potential therapeutic target...
  35. ncbi Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells
    Armelle Calipel
    INSERM U598 and IFR58, Institut Biomedical des Cordeliers, Paris 75006, France
    J Biol Chem 281:9238-50. 2006
    ..Altogether, our results suggest that the PKA/B-Raf pathway is a potential target for therapeutic strategies against (WT)B-Raf-expressing uveal melanoma...
  36. ncbi Absence of BRAF and NRAS mutations in uveal melanoma
    Frank Cruz
    Oregon Health and Science University OHSU Cancer Institute, Department of Pathology, OHSU and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Cancer Res 63:5761-6. 2003
    ..No NRAS exon 1 mutations were detected in either type of melanoma. We conclude that UMs arise independent of oncogenic BRAF and NRAS mutations, an observation that may have implications for therapies targeted to the NRAS-BRAF pathway...
  37. pmc BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
    Michele Carbone
    University of Hawai i Cancer Center, 677 Ala Moana Boulevard, Suite 901, Honolulu, HI 96813, USA
    J Transl Med 10:179. 2012
    ....
  38. ncbi Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO)
    Remi Dendale
    Department of Radiation Oncology, Curie Institut, Paris, France
    Int J Radiat Oncol Biol Phys 65:780-7. 2006
    ..This study reports the results of proton beam radiotherapy based on a retrospective series of patients treated for uveal melanoma at the Orsay Center...
  39. ncbi Monosomy 3 by FISH in uveal melanoma: variability in techniques and results
    Mary Aronow
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Surv Ophthalmol 57:463-73. 2012
    ..FISH is a widely available, versatile technology, and when performed optimally has the potential to be a valuable tool for determining the prognosis of uveal melanoma...
  40. ncbi Suppression of α5 gene expression is closely related to the tumorigenic properties of uveal melanoma cell lines
    Solange Landreville
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO, USA
    Pigment Cell Melanoma Res 24:643-55. 2011
    ..These uveal melanoma cell lines might therefore prove particularly useful as cellular models to investigate α5β1 function in the pathogenesis of invasive uveal melanoma...
  41. ncbi Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block
    Biyun Cun
    Department of Ophthalmology, Ninth People s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
    Cancer Biol Ther 13:77-84. 2012
    ..Our study suggests the viro-chemo combination therapy is feasible and is a potentially promising approach for the treatment of uveal melanoma...
  42. ncbi Prognostic factors in uveal melanoma
    A D Singh
    Oncology Service, Wills Eye Hospital, Thomas Jefferson University, 900 Walnut Street, Philadelphia, PA 19107, USA
    Melanoma Res 11:255-63. 2001
    ..At present, the role of these therapeutic methods is not clearly established...
  43. ncbi HLA expression in uveal melanoma: there is no rule without some exception
    Martine J Jager
    Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
    Hum Immunol 63:444-51. 2002
    ....
  44. ncbi Vascular endothelial growth factor a in eyes with uveal melanoma
    Guy S O Missotten
    Departments of Ophthalmology, Pathology, and Medical Statistics, Leiden University Medical Center, Leiden
    Arch Ophthalmol 124:1428-34. 2006
    ..To determine the presence of vascular endothelial growth factor A (VEGF-A) in the aqueous humor of eyes with uveal melanoma and to identify its source...
  45. pmc Authenticating cell lines in ophthalmic research laboratories
    Robert Folberg
    Oakland University William Beaumont School of Medicine, Rochester, Michigan 48309 4401, USA
    Invest Ophthalmol Vis Sci 49:4697-701. 2008
  46. ncbi Notch signaling promotes growth and invasion in uveal melanoma
    Laura Asnaghi
    Department of Pathology, Wilmer Eye Institute, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA
    Clin Cancer Res 18:654-65. 2012
    ..To determine whether uveal melanoma, the most common primary intraocular malignancy in adults, requires Notch activity for growth and metastasis...
  47. pmc Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma
    J Bauer
    Department of Dermatology, University of Tübingen Medical Center, Liebermeisterstr 25, Tubingen 72076, Germany
    Br J Cancer 101:813-5. 2009
    ..Recently, oncogenic G protein alpha subunit q (GNAQ) mutations have been described in about 50% of uveal melanomas and in the blue nevi of the skin...
  48. pmc Emerging insights into the molecular pathogenesis of uveal melanoma
    Solange Landreville
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Future Oncol 4:629-36. 2008
    ..Taken together, this pathogenetic scheme can be used to construct a molecularly based and prognostically relevant classification of uveal melanomas that can be used clinically for personalized patient management...
  49. ncbi Regulation of VEGF-A in uveal melanoma
    Mariam El Filali
    Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
    Invest Ophthalmol Vis Sci 51:2329-37. 2010
    ..This study was undertaken to examine the regulation of the proangiogenic factor vascular endothelial growth factor (VEGF-A)...
  50. pmc Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis
    T G Sheidow
    Department of Ophthalmology, University of Western Ontario, London, Canada
    Br J Ophthalmol 84:750-6. 2000
    ..To evaluate the expression of vascular endothelial growth factor (VEGF) in uveal melanomas and correlate its presence with tumour characteristics and systemic metastasis...
  51. ncbi P53 apoptosis mediator PERP: localization, function and caspase activation in uveal melanoma
    Lyndsay Davies
    Unit of Ophthalmology, School of Clinical Sciences, University of Liverpool, Liverpool, United Kingdom
    J Cell Mol Med 13:1995-2007. 2009
    ..The findings underline the apoptotic pathway mediated by PERP as a critical mechanism employed by UM tumours to modulate susceptibility to apoptosis...
  52. ncbi Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma
    Michal Lederman
    Ophthalmology, Hadassah Hebrew University Medical Center, Hebrew University School of Medicine, Jerusalem, Israel
    Curr Eye Res 33:876-84. 2008
    ..We aimed to evaluate the expression of IAPs in uveal melanoma (UM) and its correlation with prognostic factors associated with death from metastatic UM...
  53. ncbi High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients
    Cecile Laurent
    Institut Curie, Paris, France
    Cancer Res 71:666-74. 2011
    ..Our findings suggest that PTP4A3 or its cellular substrates could constitute attractive therapeutic targets to treat metastatic uveal melanomas...
  54. ncbi Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death
    Michael D Onken
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri, USA
    Cancer Res 64:7205-9. 2004
    ..These studies offer new insights into melanoma pathogenesis, and they provide a practical foundation for effective clinical predictive testing...
  55. ncbi Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis
    Shu Hong Chang
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Melanoma Res 18:191-200. 2008
    ....
  56. ncbi Uveal melanoma in Israel in the last two decades: characterization, treatment and prognosis
    Shahar Frenkel
    Department of Ophthalmology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Isr Med Assoc J 11:280-5. 2009
    ..Uveal melanoma is the most common primary intraocular tumor in adults. In the last two decades the Hadassah-Hebrew University Medical Center ocular oncology clinic has become a referral center for uveal melanoma patients...
  57. ncbi The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fine-needle aspiration biopsies
    Willem Maat
    Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands
    Arch Pathol Lab Med 131:91-6. 2007
    ..Fine-needle aspiration biopsy is being used to detect monosomy 3 in these tumors, based on the assumption that this chromosomal abnormality is distributed homogeneously throughout the tumor...
  58. pmc An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma
    Michael D Onken
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    J Mol Diagn 12:461-8. 2010
    ..This prognostic assay provides an important addition to the armamentarium for managing patients with uveal melanoma, and it provides a proof of principle for the development of similar assays for other cancers...
  59. ncbi Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens
    Carol L Shields
    Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Ophthalmology 118:396-401. 2011
    ..To determine the relationship between monosomy 3 and incidence of metastasis after genetic testing of uveal melanoma using fine-needle aspiration biopsy (FNAB)...
  60. ncbi Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target
    Charlotta All-Ericsson
    St Erik s Eye Hospital, Stockholm, Sweden
    Invest Ophthalmol Vis Sci 43:1-8. 2002
    ..To investigate the expression of the insulin-like growth factor-1 receptor (IGF-1R) with special focus on its role in cell growth in uveal melanoma...
  61. ncbi MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment
    Melanie Berube
    Oncology and Molecular Endocrinology Research Center, Center Hospitalier Universitaire de Québec, Quebec, PQ, Canada
    Mol Vis 11:1101-11. 2005
    ..The purpose of this study was to compare the expression and activity of MMP-2 in uveal melanoma cell lines grown either in vitro on plastic culture plates or in vivo as tumors produced in chick embryos...
  62. ncbi High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma
    Mohamed H Abdel-Rahman
    Department of Ophthalmology, The Ohio State University, Columbus, USA
    J Clin Oncol 24:288-95. 2006
    ..Our aim was to determine the frequency and clinical significance of PTEN alterations in uveal melanomas...
  63. ncbi Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma
    Lori A Worley
    Department of Ophthalmology and Visual Sciences, Washington University, St Louis, Missouri 63110, USA
    Clin Cancer Res 13:1466-71. 2007
    ..To compare a gene expression-based classifier versus the standard genetic prognostic marker, monosomy 3, for predicting metastasis in uveal melanoma...
  64. ncbi Lack of BRAF mutations in uveal melanoma
    Donata Rimoldi
    Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Switzerland
    Cancer Res 63:5712-5. 2003
    ....
  65. ncbi Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma
    Yixiong Zhou
    Department of Ophthalmology, Ninth People s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
    Pigment Cell Melanoma Res 23:661-74. 2010
    ..01). Our findings indicate that radioresponsive gene therapy has the potential to be a more effective and specific therapy for UM because the therapeutic gene can be spatially or temporally controlled by exogenous radiation...
  66. ncbi Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma
    Alexander Schmittel
    Department of Internal Medicine III Haematology, Oncology and Transfusion Medicine, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Melanoma Res 15:205-7. 2005
    ..9-13.8). Grade 3 and 4 thrombopenia and leucopenia occurred in eight and nine of the 19 patients, respectively. The addition of cisplatin to the GeT regimen results in excessive haematological toxicity without improvement in efficacy...
  67. ncbi Incidence of uveal melanoma in Sweden from 1960 to 1998
    Louise Bergman
    St Eriks Eye Hospital and Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Invest Ophthalmol Vis Sci 43:2579-83. 2002
    ..To investigate the incidence of uveal melanoma in Sweden during the period from 1960 to 1998, with respect to age distribution, gender, and changes in incidence over time...
  68. ncbi Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study
    Kandalam Mallikarjuna
    Department of Ocular Pathology, Medical and Vision Research Foundation, Sankara Nethralaya, Chennai, India
    Curr Eye Res 32:281-90. 2007
    ..HGF was negative in all the six tumors that had liver metastasis. Further studies are required to understand the possible mechanism of ligand-independent c-Met activation in patients with uveal melanoma...
  69. ncbi Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications
    Mario A Economou
    Cellular and Molecular Tumor Pathology, Department of Oncology and Pathology, Karolinska Hospital, Stockholm, Sweden
    Invest Ophthalmol Vis Sci 46:4372-5. 2005
    ..Their role as a prognostic factor was also clarified...
  70. ncbi Long-term survival of uveal melanoma patients after surgery for liver metastases
    S Frenkel
    Department of Ophthalmology, Hadassah University Medical Center, PO Box 12000, Jerusalem 91120, Israel
    Br J Ophthalmol 93:1042-6. 2009
    ..To evaluate the posthepatectomy survival of uveal melanoma patients with liver metastases...
  71. ncbi Variates of survival in metastatic uveal melanoma
    Petra Rietschel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:8076-80. 2005
    ..We evaluated the survival of our patients with metastatic uveal melanoma, described factors that correlated with survival, and evaluated the influence of screening tests on time of detection and survival...
  72. ncbi Variation of monosomy 3 status within uveal melanoma
    Lynn Schoenfield
    Department of Anatomic Pathology, and the Cole Eye Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Arch Pathol Lab Med 133:1219-22. 2009
    ..Monosomy 3, one such variable, can be determined using fluorescence in situ hybridization, either on enucleated samples, fine-needle aspiration biopsy, or tumor sample obtained by vitrector...
  73. ncbi Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie
    P Mariani
    Department of Surgery, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Eur J Surg Oncol 35:1192-7. 2009
    ..Uveal melanoma is characterised by a high prevalence of liver metastases and a poor prognosis...
  74. ncbi Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines
    S A Ijland
    Department of Ophthalmology, Leiden University Medical Center, The Netherlands
    Melanoma Res 9:445-50. 1999
    ..The expression of VEGF and angiopoietin-2 in combination with a lack of angiopoietin-1 expression suggest high vascular remodelling capacity and could be of great relevance for the metastatic potential of uveal melanoma...
  75. ncbi Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model
    Hua Yang
    Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Curr Eye Res 31:557-62. 2006
    ..To evaluate the combined effect of neoadjuvant intracameral interferon alpha -2b and adjuvant low-dose angiostatin in reducing the number of hepatic micrometastases in a murine model of ocular melanoma...
  76. pmc Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma
    Evangelos S Gragoudas
    Clinical Research Unit, Retina Service, Massachusetts Eye and Ear Infirmary, Boston, USA
    Trans Am Ophthalmol Soc 100:43-8; discussion 48-9. 2002
    ..To quantitate long-term risk of local treatment failure after proton irradiation of choroidal/ciliary body melanomas and to evaluate risk of metastasis-related deaths after local failure...
  77. ncbi Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma
    Young Sun
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO, USA
    Invest Ophthalmol Vis Sci 46:1561-4. 2005
    ..The current study was conducted to analyze the functional integrity of the p53 pathway in primary uveal melanoma cells...
  78. ncbi Expression and prognostic significance of iNOS in uveal melanoma
    C Christian Johansson
    Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 126:2682-9. 2010
    ..In conclusion, iNOS predicts DSS in UM and may play a role in disease progression but it is not an independent prognostic factor...
  79. ncbi The spatial distribution of monosomy 3 and network vasculogenic mimicry patterns in uveal melanoma
    Tal Meir
    Department of Ophthalmology, Hadassah Hebrew University Medical Center and The Hebrew University School of Medicine, Jerusalem, Israel
    Invest Ophthalmol Vis Sci 48:1918-22. 2007
    ..This study was conducted to assess the spatial correlation among chromosome 3 aberrations and networks in UM...
  80. ncbi Incidence of uveal melanoma in Europe
    Gianni Virgili
    Department of Ophthalmology, University of Florence, Florence, Italy
    Ophthalmology 114:2309-15. 2007
    ..To estimate incidence rates of uveal melanoma in Europe from 1983 to 1994...
  81. ncbi Occupational risk factors, ultraviolet radiation, and ocular melanoma: a case-control study in France
    P Guenel
    INSERM Unité 88, Hopital National de Saint Maurice, Saint Maurice, France
    Cancer Causes Control 12:451-9. 2001
    ..Ultraviolet radiation has been suspected as a possible cause of ocular melanoma. Because this association is controversial, we examine the role of occupational exposure to ultraviolet radiation on the occurrence of this rare cancer...
  82. ncbi Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma
    F Tschentscher
    Institut fur Humangenetik, Universitatsklinikum Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Cancer Res 61:3439-42. 2001
    ..5 Mb in 3p25. This SRO does not overlap with the VHL gene. Our finding suggests a role for two tumor suppressor genes in metastasizing uveal melanoma and may explain the loss of an entire chromosome 3 in these tumors...
  83. pmc Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R
    P Gravells
    Department of Oncology, Faculty of Medicine Dentistry and Health Sciences, The Institute for Cancer Studies, University of Sheffield, Sheffield S10 2RX, UK
    Br J Cancer 104:1098-105. 2011
    ..To investigate why UM are so chemo-resistant we explored the effect of interstrand cross-linking agents mitomycin C (MMC) and cisplatin in comparison with hydroxyurea (HU)...
  84. ncbi What hope for the future? GNAQ and uveal melanoma
    Karen Sisley
    Academic Unit of Ophthalmology and Orthoptics, Department of Oncology, K Floor, School of Medicine and Biomedical Sciences, Faculty of Medicine, Dentistry and Health, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
    Br J Ophthalmol 95:620-3. 2011
    ..Here, the authors review the background to GNAQ in UM and explore what makes it such an interesting target for the future treatment of patients...
  85. ncbi Genetic determinants of uveal melanoma
    Jerome Couturier
    Department of Genetics, Institut Curie Hôpital, Paris, France
    Dev Ophthalmol 49:150-65. 2012
    ..3, coding for a protein promoting cell migration, is highly overexpressed in class 2 tumors. The overall expression signature of class 2 tumors suggests they may originate from neuroectodermal stem cells...
  86. ncbi Expression of CD133 and other putative stem cell markers in uveal melanoma
    Michelle Thill
    Department of Ophthalmology, Clinic for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Melanoma Res 21:405-16. 2011
    ..Further experiments are needed to isolate stem cell marker-positive cells, to evaluate their functional properties and to explore therapeutical approaches to these putative CSCs in uveal melanoma...
  87. ncbi Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas
    Helena Pópulo
    Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
    Br J Ophthalmol 95:715-9. 2011
    ..To study the GNAQ mutational status in a series of uveal melanomas and evaluate possible associations with mitogen-activated protein kinase (MAPK) pathway protein expression and tumour proliferation markers...
  88. ncbi Pathology and genetics of uveal melanoma
    Klaus G Griewank
    Department of Dermatology, University Hospital Essen, Essen, Germany
    Pathology 45:18-27. 2013
    ..In this review, we summarise the clinical, pathological and genetic features of uveal melanoma, with emphasis on recent discoveries...
  89. ncbi The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma
    S E Coupland
    Department of Pathology, University Hospital Benjamin Franklin, Free University, Berlin, Germany
    J Pathol 191:120-6. 2000
    ..The expression of cyclin D1 in uveal melanoma is associated with a more aggressive course and histologically unfavourable disease. This could serve as a further independent prognostic factor in uveal melanoma...
  90. pmc Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases
    Haochuan Li
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9057, USA
    Invest Ophthalmol Vis Sci 50:5522-8. 2009
    ..To determine whether blocking the expression of the chemokine receptor CXCR4 using siRNA inhibits chemotactic responses of human uveal melanoma cells to liver-derived factors and prevents liver metastases...
  91. ncbi Multiple locations on chromosome 3 are the targets of specific deletions in uveal melanoma
    N A Cross
    Academic Unit of Ophthalmology and Orthoptics, Division of Clinical Sciences South, University of Sheffield, UK
    Eye (Lond) 20:476-81. 2006
    ..Therefore, the purpose of this investigation was to determine the location of these partial deletions of chromosome 3 in uveal melanomas...
  92. ncbi Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma
    Sarah L Lake
    Pathology Department, School of Cancer Studies, University of Liverpool, Liverpool, UK
    Invest Ophthalmol Vis Sci 51:4884-91. 2010
    ..To detect deletions and loss of heterozygosity of chromosome 3 in a rare subset of fatal, disomy 3 uveal melanoma (UM), undetectable by fluorescence in situ hybridization (FISH)...
  93. pmc ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity
    Solange Landreville
    Departments of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO, USA Département d Ophtalmologie, Universite Laval, Quebec, QC, Canada Department of Otolaryngology, Washington University School of Medicine, St Louis, MO, USA
    Pigment Cell Melanoma Res 24:430-7. 2011
    ..These findings suggest that some uveal melanoma cells have greater potential for metastasis than others and that a better understanding of such cells may be necessary for more successful therapies for metastatic melanoma...
  94. ncbi Translating uveal melanoma cytogenetics into clinical care
    Bertil Damato
    Liverpool Ocular Oncology Centre, St Paul s Eye Clinic, Royal Liverpool University Hospital, Liverpool, England
    Arch Ophthalmol 127:423-9. 2009
    ..To report our experience in translating uveal melanoma cytogenetics to routine clinical practice...
  95. pmc Identification of differentially expressed genes in uveal melanoma using suppressive subtractive hybridization
    Solange Landreville
    LOEX CUO Recherche, Centre Hospitalier Affilie Universitaire De Quebec, Hôpital du Saint Sacrement, and Département d ophtalmologie, Faculte de Medecine, Universite Laval, Quebec, Quebec, Canada
    Mol Vis 17:1324-33. 2011
    ..This study attempts to identify changes in the patterns of gene expression that lead to malignant transformation and proliferation of normal uveal melanocytes (UVM) using the Suppressive Subtractive Hybridization (SSH) technique...
  96. ncbi Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures
    K Valyi-Nagy
    Department of Pathology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA
    Cancer Gene Ther 17:223-34. 2010
    ..These findings indicate that 3D tumor cell cultures can be used to identify distinct tumor cell populations with increased resistance to HSV-1 and to explore mechanisms of ECM-mediated tumor resistance to oncolytic virotherapy...
  97. pmc Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF)
    M J Hendrix
    Department of Anatomy and Cell Biology, Iowa Cancer Center, The University of Iowa College of Medicine, Iowa City 52242 1109, USA
    Am J Pathol 152:855-63. 1998
    ..Foci of metastatic melanoma to the liver stain diffusely for HGF/SF. Regulation of the uveal melanoma interconverted phenotype by HGF/SF may play an important role in the dissemination of this tumor...
  98. pmc Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth
    Mariam El Filali
    Department of Ophthalmology, Leiden University Medical Centre, Leiden, The Netherlands
    Mol Vis 14:1752-9. 2008
    ....
  99. pmc In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases
    Hua Yang
    Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, USA
    Melanoma Res 18:95-103. 2008
    ..These cells formed hepatic micrometastases in NU/NU mice after PC inoculation or tail vein injection, with significantly more micrometastases developing in the PC inoculation model than after tail vein injection...
  100. ncbi Mortality after uveal and conjunctival melanoma: which tumour is more deadly?
    Emma Kujala
    Department of Ophthalmology, Helsinki University Central Hospital, Finland
    Acta Ophthalmol 87:149-53. 2009
    ..We aimed to model and compare mortality rates for uveal melanoma (UM) and conjunctival melanoma (CM) by adjusting for differences in tumour size and local recurrence...
  101. pmc Role of tumor invasiveness, the extracellular matrix, and chromatin sequestration in the susceptibility of uveal melanoma to herpes simplex virus type 1
    Klara Valyi-Nagy
    Department of Pathology, University of Illinois at Chicago, College of Medicine, 840 South Wood Street, Room 110, M C 847, Chicago, IL 60612, USA
    Exp Eye Res 84:991-1000. 2007
    ..Furthermore, these findings indicate for the first time that HSV-1 infection is associated with global exposure of normally highly sequestered cellular DNA in malignant cells...

Research Grants28

  1. OCULAR MELANOMA
    Paul Finger; Fiscal Year: 2003
    ..Standardized clinical and data collection procedures will be employed, and standardized forms will be used in all centers. Central training and certification of all study staff will be required. ..
  2. AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
    Pierre L Triozzi; Fiscal Year: 2010
    ....
  3. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
    ..Micrometastases, microscopic deposits of tumor that have spread via the bloodstream, are present in many patients with uveal melanoma at diagnosis. This project will test new methods of identifying and inhibiting these deposits. ..
  4. THE ROLE OF RB IN THE RETINA & OTHER TISSUES
    JAMES HARBOUR; Fiscal Year: 2009
    ..Consequently, these aims are highly relevant to the vision statement of the NEI, and they address several major program goals and objectives of the Retinal Diseases Program. ..
  5. MICROCIRCULATION OF UVEAL MELANOMA
    Robert Folberg; Fiscal Year: 2007
    ..abstract_text> ..
  6. Control of Eye Melanoma Metastsis
    Hans E Grossniklaus; Fiscal Year: 2010
    ..The third aim determines the mechanism of combined angiostatin/IFN control of the micrometastases using methods in the first two aims. ..
  7. Control of Eye Melanoma Metastasis
    Hans Grossniklaus; Fiscal Year: 2003
    ..Both the IFN and angiostatin will prevent the progression of micrometastases into metastases by anti-angiogenesis. Angiostatin will prevent metastases by an anti-melanoma invasion effect. ..
  8. SUBMACULAR SURGERY TRIALS PATHOLOGY CENTER
    Hans Grossniklaus; Fiscal Year: 2003
    ..Additionally, eyes obtained post-mortem from patients enrolled in the SST will be studied for pathologic correlation with clinical findings and outcomes. ..
  9. Thyroid Stimulating Hormone Promotes the Growth and Progression of Human Melanoma
    Julie Ellerhorst; Fiscal Year: 2008
    ..Furthermore, melanoma cases may be prevented by heightened surveillance of individuals with a history of hypothyroidism. [unreadable] [unreadable] [unreadable]..
  10. Autoimmune Mechanisms in the Response to Renal Cancer
    Julie Ellerhorst; Fiscal Year: 2006
    ..These data will be clinically useful in predicting outcomes of RCC patients, as well as in the understanding of basic mechanisms of host-derived tumor control. ..
  11. TRH Production and Regulation by Human Melanoma
    Julie Ellerhorst; Fiscal Year: 2006
    ..In Specific Aim #2, cell lines will be used for in vitro studies to determine if one or more of the mechanisms of hypothalamic TRH regulation are relevant to the control of TRH production by melanoma cells. [unreadable] [unreadable]..
  12. Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
    Gary K Schwartz; Fiscal Year: 2010
    ..Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule. ..
  13. Prediction of Second Cancer Risks for Children Treated with Proton - vs. - Photon
    Wayne D Newhauser; Fiscal Year: 2010
    ..In the future, we expect that the lower-risk treatments will result in fewer second cancers and this will translate into longer, higher-quality lives for survivors of childhood cancer (presently 270,000 persons in the United States). ..
  14. TARGETING SIGNALING OF THE TISSUE FACTOR PATHWAY
    Wolfram Ruf; Fiscal Year: 2007
    ..abstract_text> ..
  15. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2008
    ..Continue to examine the mechanisms by which flavopiridol potentiates CPT-11 induced apoptosis, which should provide the opportunity to identify new biomarkers of response for these flavopiridol drug combinations. ..
  16. PAR SIGNALING AND PROTECTIVE PATHWAYS IN INFLAMMATION AND SEPSIS
    Wolfram Ruf; Fiscal Year: 2010
    ..3. ..
  17. COLLABORATIVE OCULAR MELANOMA STUDY
    FREDERICK DAVIDORF; Fiscal Year: 2003
    ..Standardized clinical and data collection procedures will be employed, and standardized forms will be used in all centers. Central training and certification of all study staff will be required. ..
  18. Fourth NEI Symposium on the Epidemiology of Eye Diseases and Vision Disorders
    Barbara Hawkins; Fiscal Year: 2007
    ..Guest editors from the Planning Committee will be responsible for peer review and other scientific editorial tasks for manuscripts submitted for publication in the special issue of the journal. ..
  19. Phase I Trial of Safingol and Cisplatin
    Gary Schwartz; Fiscal Year: 2006
    ..conduct "proof of principle" biological assays to measure the degree of ceramide production and/or S1P inhibition, either of which may be predictive of clinical outcome or toxicity. ..
  20. MENTORING FOR NEW CANCER THERAPEAUTICS
    Gary Schwartz; Fiscal Year: 2005
    ..This K24 award mechanism represents the essence of what we are proposing and for which support is needed. ..
  21. OCULAR MELANOMA
    Barbara Hawkins; Fiscal Year: 2003
    ..Standardized clinical and data collection procedures will be employed, and standardized forms will be used in all centers. Central training and certification of all study staff will be required. ..
  22. Inhibition of CNV using a transgenic PEDF model
    Elia Duh; Fiscal Year: 2004
    ..In addition, our studies will provide a new experimental approach for the study of candidate inhibitors of CNV, providing important data regarding efficacy, therapeutic dose, frequency of administration, and toxicity. ..
  23. FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORS
    Liliana Ossowski; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  24. OCULAR MELANOMA
    Dennis Robertson; Fiscal Year: 2003
    ..Standardized clinical and data collection procedures will be employed; and standardized forms will be used in all centers. Central training and certification of all study staff will be required. ..
  25. Targeting Vasculogenesis and Interstitial Hypertension in Neurofibromatosis Type1
    Ugur Ozerdem; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  26. Experimental Uveal Melanoma and Ocular Immune Privilege
    KYLE MCKENNA; Fiscal Year: 2007
    ..abstract_text> ..